What was studied?
The phase 3 GLORY-2 study randomized Chinese adults with obesity to mazdutide or placebo alongside shared lifestyle support.
What did the researchers report?
The study reported greater sixty-week weight reduction with mazdutide. Gastrointestinal adverse reactions were more frequent in the active-treatment group.
What are the limits?
This population and regimen differ from other mazdutide trials. A weight endpoint does not establish every long-term health outcome, and adverse effects remain part of the interpretation.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.